research products  biotime inc menu research products biotime is leading the regenerative revolution by developing and marketing a growing portfolio of advanced human stem cellbased products used by researchers working in universities research institutions bioscience and biopharmaceutical industries as well as government laboratories worldwide these products are developed internally or in conjunction with biotime’s family of companies and are marketed through biotime’s esi bio division esi biocom many of these products are provided at a research grade and a clinical grade making it more efficient for researcher to transfer their research discoveries into clinical applications     current research products include human embryonic stem cells hesc developed by biotime’s singaporebased subsidiary es cell international pte ltd “esi” esi’s hesc are approved by the national institutes of health “nih” and can be provided at a research grade or manufactured under current good manufacturing practices ‘cgmp purestem® human embryonic progenitors hep that are unique progenitor cells derived from hesc and have a wide variety of advantages over pluripotent hesc as well as adult stem cells in scientific research and potential clinical applications hystem® hydrogel products a family of unique biomaterials that can be used in the laboratory to mimic a living cell’s natural environment called an extracellular matrix ecm these materials have applications in cell culture stem cell growth and tissue engineering hystem can be provided at a clinical grade making them useful for regenerative medicine cell based therapies and as delivery vehicles for bioactive molecules cell culture reagents including culture media small molecules antibodies and kits for cell differentiation and reprogramming intellectual property biotime’s research products and technologies including its hesc its purestem embryonic progenitor cells its hystem hydrogel products and its growing portfolio of stem cell culture reagents are protected by a strong portfolio of intellectual property developed internally through its family of companies or licensed from other entities products  pipelinerenevia® renevia® – french renevia® – italian renevia® – spanish opregen® purestem® progenitors astopc astvac  astvac cancer diagnostics genecards suite hextend® research products home  biotime inc menu leading the regenerative medicine revolution pursuing cures for degenerative diseases advancing clinical trials on multiple platforms cell therapies  aesthetics  ophthalmics targeting root causes and potential cures regenerative technologies our focus biotime is building a dominant company in the field of regenerative medicine our strategy is to be the leader in the development of pluripotent stem cellbased technologies and to apply those new technologies in the treatment of degenerative diseases that afflict large numbers of people worldwide we have advanced additional products into human clinical trials over the past year we are committed to leading the regenerative medicine revolution to realize the promise of our revolutionary therapies by advancing the development of our clinical products and technologies our goal is to find cures for serious degenerative diseases that afflict people worldwide through the commitment from our family of companies and our dedicated scientists and employees we are working to bring revolutionary new regenerative medicines to patients with chronic and degenerative diseases more videos ›latest news oncocyte to report second quarter financial results on august   july   biotime receives dsmb approval to start third patient cohort in clinical trial for dryamd commences patient enrollment in the us july   oncocyte receives  million in proceeds from exercise of warrants july   more news › events q  biotime inc earnings conference call august   key opinion leader lunch dry amd july   agex therapeutics a discussion with dr aubrey de grey july   more events › home  biotime inc menu leading the regenerative medicine revolution pursuing cures for degenerative diseases advancing clinical trials on multiple platforms cell therapies  aesthetics  ophthalmics targeting root causes and potential cures regenerative technologies our focus biotime is building a dominant company in the field of regenerative medicine our strategy is to be the leader in the development of pluripotent stem cellbased technologies and to apply those new technologies in the treatment of degenerative diseases that afflict large numbers of people worldwide we have advanced additional products into human clinical trials over the past year we are committed to leading the regenerative medicine revolution to realize the promise of our revolutionary therapies by advancing the development of our clinical products and technologies our goal is to find cures for serious degenerative diseases that afflict people worldwide through the commitment from our family of companies and our dedicated scientists and employees we are working to bring revolutionary new regenerative medicines to patients with chronic and degenerative diseases more videos ›latest news oncocyte to report second quarter financial results on august   july   biotime receives dsmb approval to start third patient cohort in clinical trial for dryamd commences patient enrollment in the us july   oncocyte receives  million in proceeds from exercise of warrants july   more news › events q  biotime inc earnings conference call august   key opinion leader lunch dry amd july   agex therapeutics a discussion with dr aubrey de grey july   more events › home  biotime inc menu leading the regenerative medicine revolution pursuing cures for degenerative diseases advancing clinical trials on multiple platforms cell therapies  aesthetics  ophthalmics targeting root causes and potential cures regenerative technologies our focus biotime is building a dominant company in the field of regenerative medicine our strategy is to be the leader in the development of pluripotent stem cellbased technologies and to apply those new technologies in the treatment of degenerative diseases that afflict large numbers of people worldwide we have advanced additional products into human clinical trials over the past year we are committed to leading the regenerative medicine revolution to realize the promise of our revolutionary therapies by advancing the development of our clinical products and technologies our goal is to find cures for serious degenerative diseases that afflict people worldwide through the commitment from our family of companies and our dedicated scientists and employees we are working to bring revolutionary new regenerative medicines to patients with chronic and degenerative diseases more videos ›latest news oncocyte to report second quarter financial results on august   july   biotime receives dsmb approval to start third patient cohort in clinical trial for dryamd commences patient enrollment in the us july   oncocyte receives  million in proceeds from exercise of warrants july   more news › events q  biotime inc earnings conference call august   key opinion leader lunch dry amd july   agex therapeutics a discussion with dr aubrey de grey july   more events › home  biotime inc menu leading the regenerative medicine revolution pursuing cures for degenerative diseases advancing clinical trials on multiple platforms cell therapies  aesthetics  ophthalmics targeting root causes and potential cures regenerative technologies our focus biotime is building a dominant company in the field of regenerative medicine our strategy is to be the leader in the development of pluripotent stem cellbased technologies and to apply those new technologies in the treatment of degenerative diseases that afflict large numbers of people worldwide we have advanced additional products into human clinical trials over the past year we are committed to leading the regenerative medicine revolution to realize the promise of our revolutionary therapies by advancing the development of our clinical products and technologies our goal is to find cures for serious degenerative diseases that afflict people worldwide through the commitment from our family of companies and our dedicated scientists and employees we are working to bring revolutionary new regenerative medicines to patients with chronic and degenerative diseases more videos ›latest news oncocyte to report second quarter financial results on august   july   biotime receives dsmb approval to start third patient cohort in clinical trial for dryamd commences patient enrollment in the us july   oncocyte receives  million in proceeds from exercise of warrants july   more news › events q  biotime inc earnings conference call august   key opinion leader lunch dry amd july   agex therapeutics a discussion with dr aubrey de grey july   more events › products  pipeline  biotime inc menu products  pipeline biotime inc btx – product pipeline analysis  update – site title skip to content site title menu search search for text widget this is a text widget which allows you to add text or html to your sidebar you can use them to display text links images html or a combination of these edit them in the widget section of the customizer biotime inc btx – product pipeline analysis  update posted on july   by eric bendic report hive market research released a new research report of  pages on title ” biotime inc btx – product pipeline analysis  update “with detailed analysis forecast and strategies summary biotime inc biotime is a biotechnology company which focuses on regenerative medicine and plasma volume expanders the company’s hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery emergency trauma treatment and other applications the company is also developing renevia to facilitate cell transplantation astvac and astvac autologous patientspecific cancer vaccine premvia for tendon and woundmanagement applications opregen for the treatment of dry form of agerelated macular degeneration amd astopc for spinal cord injury rehabilitation hystem hydrogel products and mobile health software products the company’s products can be used in oncology neuroscience orthopedics and blood and vascular diseases the company’s products are developed on its pluripotent stem technology the company has operations in the us hong kong israel and singapore biotime is headquartered in california the us request free research sample httpswwwreporthivecomrequestsamplephpid this report is a source for data analysis and actionable intelligence on the company’s portfolio of pipeline products the report provides key information about the company its major products and brands the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage scope – the report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developments – the report analyzes all pipeline products in development for the company biotime inc – the report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial status – the report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch date – the report provides detailed description of products in development technical specification and functions – the report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design  trial status and phase estimated start and end date reasons to buy – develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape – design and develop your product development marketing and sales strategies by understanding the competitor portfolio – to formulate effective research  development strategies – develop marketentry and market expansion strategies – exploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust return – plan mergers and acquisitions effectively by identifying key players of the most promising pipeline – identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage – develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials stage and of development etc – identify understand and capitalize the next highvalue products that your competitor would add in its portfolio note some sections may be missing if data is unavailable for the company table of contents table of contents  list of tables  list of figures  biotime inc company overview  biotime inc company snapshot  biotime inc pipeline products and ongoing clinical trials overview  browse full report httpswwwreporthivecomdetailsbiotimeincbtxproductpipelineanalysisupdate biotime inc – pipeline analysis overview  business description  biotime inc – key facts  biotime inc – major products and services  biotime inc pipeline products by development stage  biotime inc ongoing clinical trials by trial status  biotime inc pipeline products overview  biotime films  biotime films product overview  key questions answered in the report · what will the market size and the growth rate be in  · what are the key factors driving the biotime inc market · what are the key market trends impacting the growth of the biotime inc market · what are the challenges to market growth · who are the key vendors in this market space · what are the market opportunities and threats faced by the vendors in the biotime inc market · trending factors influencing the market shares of the americas apac and emea · what are the key outcomes of the five forces analysis of the biotime inc market about us we are a leading repository of market research reports and solutions catering to industries like comm  technology energy  power food and beverages automotive  transportation healthcare  life science etc this large collection of reports assists organizations in decisionmaking on aspects such as market entry strategies market sizing market share analysis competitive analysis product portfolio analysis and opportunity analysis among others we also assist in determining the best suited and targeted report from our large repository of global reports companyspecific reports and countrylevel reports contact us mike ross marketing manager mikerossreporthivecom httpwwwreporthivecom phone   sainath nagar vadgaon sheri pune maharashtra  share thistwitterfacebookgooglelike thislike loading related leave a reply cancel reply enter your comment here fill in your details below or click an icon to log in email required address never made public name required website you are commenting using your wordpresscom account  log out  change  you are commenting using your twitter account  log out  change  you are commenting using your facebook account  log out  change  you are commenting using your google account  log out  change  cancel connecting to s notify me of new comments via email published by eric bendic view all posts by eric bendic d bloggers like this biotime inc btx  product pipeline analysis  update  openpr home categories advertising media consulting marketing research arts  culture associations  organizations business economy finances banking  insurance energy  environment fashion lifestyle trends health  medicine industry real estate  construction it new media  software leisure entertainment miscellaneous logistics  transport media  telecommunications politics law  society science  education sports tourism cars traffic submit press release submit press release free of charge pressemeldung kostenlos veröffentlichen de order credits archive press release archive news  feeds newsletter rssnewsfeeds openpr on facebook openpr on twitter about us about  faq terms conditions imprint contact   pm cet  health  medicine print biotime inc btx  product pipeline analysis  update press release from report hive biotime inc btx  product pipeline analysis  update report hive market research released a new research report of  pages on title  biotime inc btx  product pipeline analysis  update with detailed analysis forecast and strategiessummarybiotime inc biotime is a biotechnology company which focuses on regenerative medicine and plasma volume expanders the company’s hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery emergency trauma treatment and other applications the company is also developing renevia to facilitate cell transplantation astvac and astvac autologous patientspecific cancer vaccine premvia for tendon and woundmanagement applications opregen for the treatment of dry form of agerelated macular degeneration amd astopc for spinal cord injury rehabilitation hystem hydrogel products and mobile health software products the company’s products can be used in oncology neuroscience orthopedics and blood and vascular diseases the company’s products are developed on its pluripotent stem technology the company has operations in the us hong kong israel and singapore biotime is headquartered in california the us request free research sample wwwreporthivecomrequestsamplephpidthis report is a source for data analysis and actionable intelligence on the company’s portfolio of pipeline products the report provides key information about the company its major products and brands the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantagescope the report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developments  the report analyzes all pipeline products in development for the company biotime inc  the report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial status  the report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch date  the report provides detailed description of products in development technical specification and functions  the report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design  trial status and phase estimated start and end datereasons to buy develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape  design and develop your product development marketing and sales strategies by understanding the competitor portfolio  to formulate effective research  development strategies  develop marketentry and market expansion strategies  exploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust return  plan mergers and acquisitions effectively by identifying key players of the most promising pipeline  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials stage and of development etc  identify understand and capitalize the next highvalue products that your competitor would add in its portfolionote some sections may be missing if data is unavailable for the companytable of contentstable of contents  list of tables  list of figures  biotime inc company overview  biotime inc company snapshot  biotime inc pipeline products and ongoing clinical trials overview browse full report wwwreporthivecomdetailsbiotimeincbtxproductpipelibiotime inc – pipeline analysis overview  business description  biotime inc  key facts  biotime inc  major products and services  biotime inc pipeline products by development stage  biotime inc ongoing clinical trials by trial status  biotime inc pipeline products overview  biotime films  biotime films product overview key questions answered in the report· what will the market size and the growth rate be in  · what are the key factors driving the biotime inc market · what are the key market trends impacting the growth of the biotime inc market · what are the challenges to market growth · who are the key vendors in this market space · what are the market opportunities and threats faced by the vendors in the biotime inc market · trending factors influencing the market shares of the americas apac and emea · what are the key outcomes of the five forces analysis of the biotime inc marketwe are a leading repository of market research reports and solutions catering to industries like comm  technology energy  power food and beverages automotive  transportation healthcare  life science etc this large collection of reports assists organizations in decisionmaking on aspects such as market entry strategies market sizing market share analysis competitive analysis product portfolio analysis and opportunity analysis among others we also assist in determining the best suited and targeted report from our large repository of global reports companyspecific reports and countrylevel reportsmike ross marketing manager mikerossreporthivecom wwwreporthivecom phone   sainath nagar vadgaon sheri pune maharashtra this release was published on openpr newsid  • views  more releases permanent link to this press release please set a link in the press area of your homepage to this press release on openpr openpr disclaims liability for any content contained in this release  share twitter email you can edit or delete your press release here to top  openpr   imprint more releases from report hive global aluminum pigment market research report  global automatic feeding machine market research report  asia pacific maltodextrin market professional survey report   all  releases comments about openpr we publish our press releases on openprde because we like people who are open  just like usfrank obels ceo inconet  informationssysteme communication und netzwerkberatung gmbh your press releases ongoogle news openprde home  biotime inc menu leading the regenerative medicine revolution pursuing cures for degenerative diseases advancing clinical trials on multiple platforms cell therapies  aesthetics  ophthalmics targeting root causes and potential cures regenerative technologies our focus biotime is building a dominant company in the field of regenerative medicine our strategy is to be the leader in the development of pluripotent stem cellbased technologies and to apply those new technologies in the treatment of degenerative diseases that afflict large numbers of people worldwide we have advanced additional products into human clinical trials over the past year we are committed to leading the regenerative medicine revolution to realize the promise of our revolutionary therapies by advancing the development of our clinical products and technologies our goal is to find cures for serious degenerative diseases that afflict people worldwide through the commitment from our family of companies and our dedicated scientists and employees we are working to bring revolutionary new regenerative medicines to patients with chronic and degenerative diseases more videos ›latest news oncocyte to report second quarter financial results on august   july   biotime receives dsmb approval to start third patient cohort in clinical trial for dryamd commences patient enrollment in the us july   oncocyte receives  million in proceeds from exercise of warrants july   more news › events q  biotime inc earnings conference call august   key opinion leader lunch dry amd july   agex therapeutics a discussion with dr aubrey de grey july   more events › biotime inc btx  product pipeline analysis  update infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports biotime inc btx  product pipeline analysis  update biotime inc btx  product pipeline analysis  update wgr  june  global  pages globaldata description table of content sample report enquiry before buy related reports summarybiotime inc biotime is a biotechnology company it is focused on research and development in the field of regenerative medicine the company’s products can be used in various fields of medicine such as oncology neuroscience orthopedics and blood and vascular diseases it is developing medicines using pluripotent stem technology that is based on induced pluripotent stem ips cells and human embryonic stem hes cells the company is developing purestem cell lines and associated espan culture media hystem hydrogels and human embryonic stem cell lines its potential near term therapeutic and diagnostic product opportunities include renevia as a cell delivery device and pancdx as a novel bloodbased cancer screen it operates in two areas of biomedical research and product development namely plasma volume expander products and regenerative medicine the company’s lead blood plasma expander product hextend is used in the treatment of hypovolemia it operates in the us and asia biotime is headquartered in california the us biotime focuses on the commercialization of its current line of research products by building a strong operating base besides gaining expertise through agreements and collaborations and acquisitionsthis report is a source for data analysis and actionable intelligence on the company’s portfolio of pipeline products the report provides key information about the company its major products and brands the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantagescope the report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developments the report analyzes all pipeline products in development for the company biotime inc the report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial status the report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch date the report provides detailed description of products in development technical specification and functions the report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design  trial status and phase estimated start and end datereasons to buy develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape design and develop your product development marketing and sales strategies by understanding the competitor portfolio to formulate effective research  development strategies develop marketentry and market expansion strategies exploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust return plan mergers and acquisitions effectively by identifying key players of the most promising pipeline  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials stage and of development etc identify understand and capitalize the next highvalue products that your competitor would add in its portfolio table of contents table of contents list of tables list of figures biotime inc company snapshot biotime inc company overview key information biotime inc pipeline products and clinical trials overview biotime inc – pipeline analysis overview business description key facts biotime inc  major products and services biotime inc pipeline products by development stage biotime inc pipeline products overview biotime films biotime films product overview biotime sponges biotime sponges product overview hystem renevia hystem renevia product overview hystemspine hystemspine product overview hystemtendon hystemtendon product overview pancdx  bladder cancer pancdx  bladder cancer product overview pancdx  breast cancer pancdx  breast cancer product overview pancdx  colon cancer pancdx  colon cancer product overview pancdx  lung cancer pancdx  lung cancer product overview pancdx  prostate cancer pancdx  prostate cancer product overview premvia premvia product overview reglyde reglyde product overview biotime inc  key competitors biotime inc  key employees biotime inc  key employee biographies biotime inc  locations and subsidiaries head office other locations  subsidiaries recent developments biotime inc recent developments jun   biotime subsidiary asterias biotherapeutics appoints former pfizer senior executive pedro lichtinger as president and chief executive officer may   biotime receives iso  certification for medical devices may   biotime’s subsidiary asterias biotherapeutics inc settles patent interference proceedings may   biotime announces first quarter  results and recent developments may   lifemap solutions to develop mobile health products with mount sinai’s icahn school of medicine apr   biotime announces board membership changes and management and board changes at its subsidiary asterias biotherapeutics mar   biotime announces fourth quarter and fiscal year end  financial results and recent corporate accomplishments mar   biotime provides product development update jan   biotime subsidiary oncocyte corporation initiates clinical development of bladder cancer diagnostics in the united states of america and china jan   biotime’s subsidiary lifemap sciences announces release of lifemap discovery version  with geneanalytics a powerful gene expression analysis tool appendix methodology about globaldata contact us disclaimer list of tables biotime inc key facts biotime inc pipeline products and clinical trials overview biotime inc pipeline products by equipment type biotime inc pipeline products by indication biotime inc key facts biotime inc major products and services biotime inc number of pipeline products by development stage biotime inc pipeline products summary by development stage biotime films  product status biotime films  product description biotime sponges  product status biotime sponges  product description hystem renevia  product status hystem renevia  product description hystemspine  product status hystemspine  product description hystemtendon  product status hystemtendon  product description pancdx  bladder cancer  product status pancdx  bladder cancer  product description pancdx  breast cancer  product status pancdx  breast cancer  product description pancdx  colon cancer  product status pancdx  colon cancer  product description pancdx  lung cancer  product status pancdx  lung cancer  product description pancdx  prostate cancer  product status pancdx  prostate cancer  product description premvia  product status premvia  product description reglyde  product status reglyde  product description biotime inc key employees biotime inc key employee biographies biotime inc subsidiaries list of figures biotime inc pipeline products by equipment type biotime inc pipeline products by development stage  request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send btx key statistics  biotime inc financial ratios  marketwatch bulletin investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close biotime inc nyse american btx go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus biotime inc market open  real time quotes jul    am btx quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   company description biotime inc engages in biotechnology business it focuses on research and development of regenerative medicine or therapeutic products for advancement in the field of oncology orthopedics retinal and neurological diseases and disorders blood and vascular system diseases and disorders blood pla biotime inc engages in biotechnology business it focuses on research and development of regenerative medicine or therapeutic products for advancement in the field of oncology orthopedics retinal and neurological diseases and disorders blood and vascular system diseases and disorders blood plasma volume expansion diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research the company was founded by judith segall hal sternberg paul e segall and harold d waitz on november   and is headquartered in alameda ca valuation pe current  pe ratio with extraordinary items  pe ratio without extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title mr alfred dennis kingsley   chairman mr aditya p mohanty   copresident coceo  director dr michael d west   copresident coceo  director mr russell l skibsted   cfo  principal accounting officer dr hal sternberg   vice presidentresearch insider actions – purchase – sale  – number of transactions  except as otherwise noted the content of this page is licensed under the creative commons attribution  license and code samples are licensed under the apache  license for details see our site policies java is a registered trademark of oracle andor its affiliates last updated february   send feedback about this page documentation feedback freebase api deprecated product feedback cancel